Exact Mass: 501.3454052
Exact Mass Matches: 501.3454052
Found 244 metabolites which its exact mass value is equals to given mass value 501.3454052
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(9Z,12Z,15Z,18Z,21Z)-Tetracosa-9,12,15,18,21-pentaenoylcarnitine
C31H51NO4 (501.38178860000005)
(9Z,12Z,15Z,18Z,21Z)-Tetracosa-9,12,15,18,21-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z,12Z,15Z,18Z,21Z)-Tetracosa-9,12,15,18,21-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (9Z,12Z,15Z,18Z,21Z)-Tetracosa-9,12,15,18,21-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3S)-3-hydroxyoctyl]cyclopentyl]heptanoylcarnitine
7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoctyl]cyclopentyl]heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoctyl]cyclopentyl]heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoctyl]cyclopentyl]heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxyoctyl]cyclopentyl]heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6S,7S,18S)-20-aza-6,10,12,18-tetramethyl-7-O-(2,6-dideoxy-3-C-methyl-beta-D-ribo-hexopyranosyl)-cycloicosa-2,4,9,12,14-pentaen-1-one|vicenistatin M
(5S,6R)-5-(dimethylamino)-6-hydroxypoly-angioic acid|Ambruticin VS-3|ambruticin VS3
Arg Ala Gln Lys
Ala Lys Lys Arg
C21H43N9O5 (501.33869880000003)
Ala Lys Gln Arg
Ala Lys Arg Lys
C21H43N9O5 (501.33869880000003)
Ala Lys Arg Gln
Ala Gln Lys Arg
Ala Gln Arg Lys
Ala Arg Lys Lys
C21H43N9O5 (501.33869880000003)
Ala Arg Lys Gln
Ala Arg Gln Lys
Glu Ile Ile Lys
Glu Ile Lys Ile
Glu Ile Lys Leu
Glu Ile Leu Lys
Glu Lys Ile Ile
Glu Lys Ile Leu
Glu Lys Leu Ile
Glu Lys Leu Leu
Glu Leu Ile Lys
Glu Leu Lys Ile
Glu Leu Lys Leu
Glu Leu Leu Lys
Ile Glu Ile Lys
Ile Glu Lys Ile
Ile Glu Lys Leu
Ile Glu Leu Lys
Ile Ile Glu Lys
Ile Ile Lys Glu
Ile Ile Arg Thr
Ile Ile Thr Arg
Ile Lys Glu Ile
Ile Lys Glu Leu
Ile Lys Ile Glu
Ile Lys Lys Asn
Ile Lys Leu Glu
Ile Lys Asn Lys
Ile Leu Glu Lys
Ile Leu Lys Glu
Ile Leu Arg Thr
Ile Leu Thr Arg
Ile Asn Lys Lys
Ile Arg Ile Thr
Ile Arg Leu Thr
Ile Arg Thr Ile
Ile Arg Thr Leu
Ile Thr Ile Arg
Ile Thr Leu Arg
Ile Thr Arg Ile
Ile Thr Arg Leu
Lys Ala Lys Arg
C21H43N9O5 (501.33869880000003)
Lys Ala Gln Arg
Lys Ala Arg Lys
C21H43N9O5 (501.33869880000003)
Lys Ala Arg Gln
Lys Glu Ile Ile
Lys Glu Ile Leu
Lys Glu Leu Ile
Lys Glu Leu Leu
Lys Ile Glu Ile
Lys Ile Glu Leu
Lys Ile Ile Glu
Lys Ile Lys Asn
Lys Ile Leu Glu
Lys Ile Asn Lys
Lys Lys Ala Arg
C21H43N9O5 (501.33869880000003)
Lys Lys Ile Asn
Lys Lys Lys Val
Lys Lys Leu Asn
Lys Lys Asn Ile
Lys Lys Asn Leu
Lys Lys Gln Val
Lys Lys Arg Ala
C21H43N9O5 (501.33869880000003)
Lys Lys Val Lys
Lys Lys Val Gln
Lys Leu Glu Ile
Lys Leu Glu Leu
Lys Leu Ile Glu
Lys Leu Lys Asn
Lys Leu Leu Glu
Lys Leu Asn Lys
Lys Asn Ile Lys
Lys Asn Lys Ile
Lys Asn Lys Leu
Lys Asn Leu Lys
Lys Gln Ala Arg
Lys Gln Lys Val
Lys Gln Arg Ala
Lys Gln Val Lys
Lys Arg Ala Lys
C21H43N9O5 (501.33869880000003)
Lys Arg Ala Gln
Lys Arg Lys Ala
C21H43N9O5 (501.33869880000003)
Lys Arg Gln Ala
Lys Val Lys Lys
Lys Val Lys Gln
Lys Val Gln Lys
Leu Glu Ile Lys
Leu Glu Lys Ile
Leu Glu Lys Leu
Leu Glu Leu Lys
Leu Ile Glu Lys
Leu Ile Lys Glu
Leu Ile Arg Thr
Leu Ile Thr Arg
Leu Lys Glu Ile
Leu Lys Glu Leu
Leu Lys Ile Glu
Leu Lys Lys Asn
Leu Lys Leu Glu
Leu Lys Asn Lys
Leu Leu Glu Lys
Leu Leu Lys Glu
Leu Leu Arg Thr
Leu Leu Thr Arg
Leu Asn Lys Lys
Leu Arg Ile Thr
Leu Arg Leu Thr
Leu Arg Thr Ile
Leu Arg Thr Leu
Leu Thr Ile Arg
Leu Thr Leu Arg
Leu Thr Arg Ile
Leu Thr Arg Leu
Asn Ile Lys Lys
Asn Lys Ile Lys
Asn Lys Lys Ile
Asn Lys Lys Leu
Asn Lys Leu Lys
Asn Leu Lys Lys
Gln Ala Lys Arg
Gln Ala Arg Lys
Gln Lys Ala Arg
Gln Lys Lys Val
Gln Lys Arg Ala
Gln Lys Val Lys
Gln Arg Ala Lys
Gln Arg Lys Ala
Gln Val Lys Lys
Arg Ala Lys Lys
C21H43N9O5 (501.33869880000003)
Arg Ala Lys Gln
Arg Ile Ile Thr
Arg Ile Leu Thr
Arg Ile Thr Ile
Arg Ile Thr Leu
Arg Lys Ala Lys
C21H43N9O5 (501.33869880000003)
Arg Lys Ala Gln
Arg Lys Lys Ala
C21H43N9O5 (501.33869880000003)
Arg Lys Gln Ala
Arg Leu Ile Thr
Arg Leu Leu Thr
Arg Leu Thr Ile
Arg Leu Thr Leu
Arg Gln Ala Lys
Arg Gln Lys Ala
Arg Thr Ile Ile
Arg Thr Ile Leu
Arg Thr Leu Ile
Arg Thr Leu Leu
Thr Ile Ile Arg
Thr Ile Leu Arg
Thr Ile Arg Ile
Thr Ile Arg Leu
Thr Leu Ile Arg
Thr Leu Leu Arg
Thr Leu Arg Ile
Thr Leu Arg Leu
Thr Arg Ile Ile
Thr Arg Ile Leu
Thr Arg Leu Ile
Thr Arg Leu Leu
Val Lys Lys Lys
Val Lys Lys Gln
Val Lys Gln Lys
Val Gln Lys Lys
(Z)-2-hexacos-17-enamidoethanesulfonic acid
C28H55NO4S (501.38515900000004)
7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3S)-3-hydroxyoctyl]cyclopentyl]heptanoylcarnitine
(9Z,12Z,15Z,18Z,21Z)-Tetracosa-9,12,15,18,21-pentaenoylcarnitine
C31H51NO4 (501.38178860000005)
(2S,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-10-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3S)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2S,3R)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
(2R,3R)-10-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-3,4-dihydro-2H-1,5-benzoxazocin-6-one
[2-hydroxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
(4E,8E,12E)-3-hydroxy-2-(2-hydroxydodecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(E)-3-hydroxy-2-[[(4Z,7Z)-2-hydroxyhexadeca-4,7-dienoyl]amino]dec-4-ene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]trideca-4,8-diene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid
C26H47NO6S (501.31239220000003)
(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tetradec-4-ene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(4E,8E)-3-hydroxy-2-(pentadecanoylamino)dodeca-4,8-diene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyundecane-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]tridec-4-ene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(4E,8E)-3-hydroxy-2-(tridecanoylamino)tetradeca-4,8-diene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(E)-2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxydecane-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(4E,8E)-2-(decanoylamino)-3-hydroxyheptadeca-4,8-diene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(4E,8E)-3-hydroxy-2-(tetradecanoylamino)trideca-4,8-diene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]dodec-4-ene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(4E,8E)-3-hydroxy-2-(undecanoylamino)hexadeca-4,8-diene-1-sulfonic acid
C27H51NO5S (501.34877560000007)
(4E,8E)-2-(dodecanoylamino)-3-hydroxypentadeca-4,8-diene-1-sulfonic acid
C27H51NO5S (501.34877560000007)